AEON Biopharma posts $2.47M Q3 2026 net income
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AEON Biopharma reported third-quarter 2026 net income of $2.465 million, compared with a $4.538 million net loss a year earlier. Operating loss was $4.483 million, versus an operating loss of $2.493 million, while the quarter included $7.014 million from changes in warrant fair value. Research and development expense was $1.515 million, up from $597,000.
Cash and equivalents were $11.417 million as of September 30, 2026. AEON said that balance, together with approximately $6.2 million in milestone warrant proceeds received in the fourth quarter, is expected to fund operations into the second quarter of 2027. The FDA agreed in principle with a two-stage CMAP comparative pharmacodynamic study design; recommendations to strengthen assay sensitivity were incorporated into the protocol submitted with AEON’s IND. Study initiation is planned for Q1 2027. AEON also reported approximately 98% coverage of the core 150 kDa neurotoxin sequence and 100% identity across analyzed regions.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointNet income reached $2.465 million, including $7.014 million from warrant fair-value changes. 70% of market cap
Negative
- Moderate pointOperating loss widened to $4.483 million from $2.493 million.
Filing Explained
Class A shares issued and outstanding were 59,084,675 at
8-K Event Classification
Key Figures
Key Terms
Biosimilar Biological Product Development (BPD) Type 2b meeting regulatory
comparative pharmacodynamic study medical
compound muscle action potential medical
351(k) biosimilar pathway regulatory
Investigational New Drug regulatory
comparative analytical assessment technical
Earnings Snapshot
AEON expects cash and cash equivalents as of September 30, 2026, together with approximately $6.2 million in milestone warrant proceeds received in the fourth quarter of 2026, to fund operations into the second quarter of 2027.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were AEON's Q3 2026 financial results?
What study did the FDA agree to in principle for AEON's ABP-450 program?
AI-generated analysis. How Rhea-AI works. Not financial advice.
